Incidence and survival from lung cancer in Greenland is comparable to survival in the Nordic countries
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Incidence and survival from lung cancer in Greenland is comparable to survival in the Nordic countries. / Gelvan, Allan; Risum, Signe; Langer, Seppo W.
I: Danish Medical Journal, Bind 62, Nr. 4, 04.2015, s. A5033.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Incidence and survival from lung cancer in Greenland is comparable to survival in the Nordic countries
AU - Gelvan, Allan
AU - Risum, Signe
AU - Langer, Seppo W
PY - 2015/4
Y1 - 2015/4
N2 - INTRODUCTION: Oncological treatment of lung cancer has been available in Greenland since 2004. We evaluated patient characteristics and survival rates for the first six years of local lung cancer treatment.METHODS: From September 2004 to August 2010, a total of 173 patients with lung cancer were referred to treatment at Queen Ingrid's Hospital. On 1 February 2014, treatment results, survival, and prognostic variables were analysed.RESULTS: The mean age at diagnosis was 63 years. Non-small cell lung cancer (NSCLC) was diagnosed in 145 patients (84%); 56% had squamous cell carcinoma, 34% had adenocarcinoma, 2% had large cell carcinoma and 8% had NSCLC not otherwise specified (NOS). In all, 28 (16%) had small cell lung cancer. A total of 142 patients (82%) received treatment; 20 underwent surgery (ten stage Ib, one stage IIa, five stage IIb, four stage IIIa); palliative chemotherapy was given to 122 of the 142 treated patients (86%). Of these, 36 patients (30%) received second-line chemotherapy.The median survival of patients undergoing primary lobectomy/pneumonectomy, palliative chemotherapy, and no treatment was 76.3 months, 11.8 months, and 2.0 months, respectively (p < 0.0001).CONCLUSION: Evaluation of the first six years of lung cancer treatment in Greenland revealed a disease incidence and survival comparable to those found in the Nordic countries. To further decrease mortality from lung cancer, health-care resources should continue to be allocated to the prevention and treatment of lung cancer in Greenland.FUNDING: not relevant.TRIAL REGISTRATION: not relevant.
AB - INTRODUCTION: Oncological treatment of lung cancer has been available in Greenland since 2004. We evaluated patient characteristics and survival rates for the first six years of local lung cancer treatment.METHODS: From September 2004 to August 2010, a total of 173 patients with lung cancer were referred to treatment at Queen Ingrid's Hospital. On 1 February 2014, treatment results, survival, and prognostic variables were analysed.RESULTS: The mean age at diagnosis was 63 years. Non-small cell lung cancer (NSCLC) was diagnosed in 145 patients (84%); 56% had squamous cell carcinoma, 34% had adenocarcinoma, 2% had large cell carcinoma and 8% had NSCLC not otherwise specified (NOS). In all, 28 (16%) had small cell lung cancer. A total of 142 patients (82%) received treatment; 20 underwent surgery (ten stage Ib, one stage IIa, five stage IIb, four stage IIIa); palliative chemotherapy was given to 122 of the 142 treated patients (86%). Of these, 36 patients (30%) received second-line chemotherapy.The median survival of patients undergoing primary lobectomy/pneumonectomy, palliative chemotherapy, and no treatment was 76.3 months, 11.8 months, and 2.0 months, respectively (p < 0.0001).CONCLUSION: Evaluation of the first six years of lung cancer treatment in Greenland revealed a disease incidence and survival comparable to those found in the Nordic countries. To further decrease mortality from lung cancer, health-care resources should continue to be allocated to the prevention and treatment of lung cancer in Greenland.FUNDING: not relevant.TRIAL REGISTRATION: not relevant.
KW - Aged
KW - Aged, 80 and over
KW - Carcinoma, Large Cell/epidemiology
KW - Carcinoma, Non-Small-Cell Lung/epidemiology
KW - Carcinoma, Squamous Cell/epidemiology
KW - Cause of Death
KW - Chemotherapy, Adjuvant
KW - Cohort Studies
KW - Combined Modality Therapy
KW - Disease-Free Survival
KW - Female
KW - Greenland/epidemiology
KW - Humans
KW - Incidence
KW - Lung Neoplasms/mortality
KW - Male
KW - Middle Aged
KW - Neoplasm Invasiveness/pathology
KW - Neoplasm Recurrence, Local/mortality
KW - Neoplasm Staging
KW - Pneumonectomy/methods
KW - Retrospective Studies
KW - Risk Assessment
KW - Scandinavian and Nordic Countries/epidemiology
KW - Survival Analysis
KW - Treatment Outcome
M3 - Journal article
C2 - 25872548
VL - 62
SP - A5033
JO - Danish Medical Journal
JF - Danish Medical Journal
SN - 2245-1919
IS - 4
ER -
ID: 247891025